{
  "docId": "019de072-8046-72ee-8797-71c9ff7422eb",
  "docSlug": "98d74c454dfdfefd8fb9993ff5213b70",
  "documentTitle": "Hillevax | IPO Presentation Deck | 24 slides",
  "authorId": "hillevax",
  "authorName": "Hillevax",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 19,
  "pageCount": 24,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "Clinical trial design diagram showing randomization of 3,000 infants into HIL-214 and placebo groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-8046-72ee-8797-71c9ff7422eb/19",
  "deckHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb",
  "deckJsonHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb.json",
  "deckAnchorHref": "/decks/019de072-8046-72ee-8797-71c9ff7422eb#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.79,
        "x": 0.108,
        "y": 0.255
      },
      "kind": "diagram",
      "text": "Clinical trial flow from healthy infants to treatment arms to primary endpoint",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "385b4078-894c-4e85-99e8-1c9db53862a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "image",
      "text": "Map highlighting US and Latin America",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9da3abd-8d85-485f-9954-d258ef496e26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.25,
        "x": 0.025,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Topline data expected 2H23",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "930c3262-a4d1-4e62-95a7-b5fd5fa1daad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.025,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Vaccinations at Day 1 and Day 28\n2 Key secondary endpoints may include evaluation of efficacy against any GI or GII norovirus strain",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3d923bf-9563-4b28-bbe2-6508d1cfd4e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.025,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 2b pediatric study: planned start 2Q22",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09019e76-1d16-48a0-b3a3-5ebaf5565055",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Clinical Trial Design",
      "slug": null,
      "matchId": "2ba53a93-ffc9-41e9-a369-d6d1ebcdd8df",
      "evidence": "Flowchart showing patient population, intervention arms, and endpoint",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 17,
      "beatId": "f4579335-9b5d-4c59-a7d9-e31f9a2392ff",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 17-23 outline the development plan, market opportunity, and anticipated milestones",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}